| EPB0191 | Blood pressure among people living with HIV transitioning from efavirenz- to dolutegravir-based ART: a cohort study from Zimbabwe | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0192 | 96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0193 | CD4+ T lymphocyte recovery and cognitive function in women living with HIV | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0194 | Improving the safety of clients on antiretroviral therapy through Drug Use Evaluations (DUE) to manage adverse drug events at six ART sites in the Oromia region of Ethiopia | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0195 | Impact of GLP-1 receptor agonists on body weight in patients with type 2 diabetes and HIV | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0196 | Thymosin α1 in restoring immune response in immunological nonresponders | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0197 | Metabolic syndrome among persons living with HIV on DTG based antiretroviral regimen: outcomes from a longitudinal cohort study in Ghana | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0198 | A patient with undiagnosed HIV presenting with hemophagocytic lymphohistiocytosis - the importance of routine HIV testing in hospitalized patients | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0199 | Weight gain and lipid changes with switching from boosted protease inhibitor-based regimens to bictegravir/tenofovir alafenamide/emtricitabine | E-poster | Clinical complications of HIV and antiretroviral therapy |
| LBEPB12 | Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks | E-poster | Clinical complications of HIV and antiretroviral therapy |